pd 98059 has been researched along with sildenafil citrate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Das, A; Kukreja, RC; Rao, YJ; Salloum, FN; Xi, L | 1 |
| Chang, YK; Choi, DE; Chung, S; Jeong, JY; Kim, SY; Lee, KW; Lee, SJ; Lim, BJ; Na, KR; Shin, YT | 1 |
| Böhme, S; Ebner, A; Ebner, B; Reetz, A; Schauer, A; Strasser, RH; Weinbrenner, C | 1 |
3 other study(ies) available for pd 98059 and sildenafil citrate
| Article | Year |
|---|---|
ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice.
Topics: Animals; bcl-2-Associated X Protein; Cardiovascular Agents; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Enzyme Activation; Flavonoids; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hemodynamics; Male; Mice; Mice, Inbred ICR; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardial Contraction; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Signal Transduction; Sildenafil Citrate; Sulfones; Time Factors | 2009 |
Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blood Urea Nitrogen; Caspase 3; Creatinine; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Drug Administration Schedule; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Kidney Diseases; Male; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Sildenafil Citrate; Sulfones; Time Factors | 2009 |
Pharmacological postconditioning by bolus injection of phosphodiesterase-5 inhibitors vardenafil and sildenafil.
Topics: Animals; Cardiotonic Agents; Cyclic GMP; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Imidazoles; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Phosphodiesterase 5 Inhibitors; Piperazines; Protein Kinase C; Purines; Rats; Rats, Wistar; Sildenafil Citrate; Sulfones; Triazines; Vardenafil Dihydrochloride | 2013 |